Are low generics prices at risk of causing shortages and sudden spikes?

A familiar argument voiced in pharma is that the price of new drugs has to be kept high to pay for tomorrow’s medicines, and those pursuing new innovations can point to figures such as  Deloitte’s finding that return on research and development (R&D) has dropped to below 4%, to show how tough drug discovery and development has become.

But other statistics that another group of drugmakers, who are making their own enormous contribution to healthcare but are not always given the same prominence, are just as startling.

"We're trying to get people to ask: "how much are you saving versus the risks you are taking of a shortage?""